Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer
| Class:Id | LiteratureReference:2011992 |
| _displayName | Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer |
| _timestamp | 2011-11-22 14:55:09 |
| author | [Person:2011511] Bernard-Pierrot, I [Person:2011581] Gruel, N [Person:1982020] Stransky, N [Person:2011774] Vincent-Salomon, A [Person:2011700] Reyal, F [Person:2011694] Raynal, V [Person:2011770] Vallot, C [Person:2011683] Pierron, G [Person:1226106] Radvanyi, F [Person:2011536] Delattre, O |
| created | [InstanceEdit:2011993] Rothfels, K, 2011-11-22 |
| journal | Cancer Res |
| pages | 7165-75 |
| pubMedIdentifier | 18757432 |
| title | Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer |
| volume | 68 |
| year | 2008 |
| (literatureReference) | [Pathway:1839120] Signaling by FGFR1 amplification mutants [Homo sapiens] [Reaction:2077420] FGFR3 mutants bind and are inactivated by tyrosine kinase inhibitors [Homo sapiens] |
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer (2011992)